NasdaqGM:APGEBiotechs
Apogee Therapeutics (APGE) Is Down 7.1% After Positive Yearlong Zumilokibart Data - Has The Bull Case Changed?
Apogee Therapeutics recently reported positive 52-week maintenance data from Part A of its Phase 2 APEX trial of zumilokibart in moderate-to-severe atopic dermatitis, showing durable responses and a safety profile generally in line with other drugs in the class.
The data highlight the potential for meaningfully less frequent dosing than many existing treatments, while still delivering deepening improvements in skin lesions and itch over a full year.
Next, we’ll examine how the prospect of...